Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지

Useful Biomarkers for the Diagnosis of Endometriosis

자궁내막증 진단을 위한 생표지자의 유용성

  • Kim, Sun-Young (Department of Obstetrics and Gynecology, College of Medicine, Yonsei University, Gangnam Severance Hospital) ;
  • Lee, Byung-Seok (Department of Obstetrics and Gynecology, College of Medicine, Yonsei University, Gangnam Severance Hospital)
  • 김선영 (연세대학교 의과대학 산부인과학교실 강남세브란스 병원) ;
  • 이병석 (연세대학교 의과대학 산부인과학교실 강남세브란스 병원)
  • Published : 2010.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

진단적 복강경을 하지 않으면 자궁내막증의 진단이 불가능하다는 점은 의사들이 해결해야 할 과제 중 하나이다. 아직까지는 자궁내막증을 진단할 수 있는 획기적인 표지자가 없기 때문에 CA-125 같은 종양 표지자의 혈중 농도를 측정하였으나 진단 도구로 이용하기에는 한계가 있다. 이러한 이유로 초기 자궁내막증을 진단할 수 있는 방법을 연구하기 위한 여러 시도들이 있었는데 특히 자궁내막증 1, 2기 환자에서 병의 초기 상태에 복강경적 치료를 하였을 경우 자연 임신 성공률이 2배 가까이 높은 것으로 보고되었기 때문에 불임 여성에 있어 자궁내막증의 진단 시기는 임상적으로도 그 중요성이 매우 크다고 할 수 있겠다. CA-125는 자궁내막증 환자의 추적관찰에 있어 특이도가 높은 편이며 효용성이 있는데 특히 수술적 치료 후 장기적으로 병의 활성 혹은 재발을 평가하는데 있어 유용하다. 무작위적인 임상 연구 결과 자궁내막증과 관련된 불임이나 통증은 수술적 치료시 분명한 이득이 있는 것으로 보고된 바84 자궁내막증은 적절한 진단과 치료가 중요한 질환이라는 점을 다시 한번 상기해야 한다. 또한 병의 진행에 따른 여러 면역학적인 변화들이 확인되면서 자궁내막증의 진단에 있어 면역학적 표지자의 중요성이 부각되고 있다. 그 중에서도 복막액이나 혈청 내 사이토카인은 진단 도구로서 그 가능성에 주목을 받고 있으며 이에 대한 대규모 연구가 추후 필요할 것으로 사료된다. 최근의 면역학적 발견과 DNA 기술 발전은 자궁내막증의 진단에 있어 핵심적인 screening 도구의 발견에 일조할 것이며 이러한 기술적 발전을 근간으로 하여 머지 않아 획기적인 표지자가 개발될 것으로 기대한다.

Keywords

References

  1. Revised American Fertility Society classification of endometriosis. Fertil Steril 1985; 43: 351-2. https://doi.org/10.1016/S0015-0282(16)48430-X
  2. Meden H, Fattahi-Meibodi A. CA 125 in benign gynecological conditions. Int J Biol Markers 1998; 13: 231-7. https://doi.org/10.1177/172460089801300411
  3. Pittaway DE, Fayez JA. Serum CA-125 antigen levels increase during menses. Am J Obstet Gynecol 1987; 156: 75-6. https://doi.org/10.1016/0002-9378(87)90207-9
  4. Pittaway DE, Fayez JA. The use of CA-125in the diagnosis and management of endometriosis. Fertil Steril 1986; 46: 790 -5. https://doi.org/10.1016/S0015-0282(16)49812-2
  5. Moretuzzo RW, DiLauro S, Jenison E, Chen SL, Reindollar RH, McDonough PG. Serum and peritoneal lavage fluid CA-125 levels in endometriosis. Fertil Steril 1988; 50: 430-3. https://doi.org/10.1016/S0015-0282(16)60127-9
  6. Barbati A, Cosmi EV, Spaziani R, Ventura R, Montanino G. Serum and peritoneal fluid CA-125 levels in patients with endometriosis. Fertil Steril 1994; 61: 438-42. https://doi.org/10.1016/S0015-0282(16)56572-8
  7. Mol BW, Bayram N, Lijmer JG, Wiegerinck MA, Bongers MY, van der Veen F, et al. The performance of CA-125 measurement in the detection of endometriosis: a metaanalysis. Fertil Steril 1998; 70: 1101-8. https://doi.org/10.1016/S0015-0282(98)00355-0
  8. Pittaway DE, Rondinone D, Miller KA, Barnes K. Clinical evaluation of CA-125 concentrations as a prognostic factor for pregnancy in infertile women with surgically treated endometriosis. Fertil Steril 1995; 64: 321-4. https://doi.org/10.1016/S0015-0282(16)57730-9
  9. Fedele L, Arcaini L, Vercellini P, Bianchi S, Candiani GB. Serum CA 125 measurements in the diagnosis of endometriosis recurrence. Obstet Gynecol 1988; 72: 19-22.
  10. Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001; 102: 5-14.
  11. Bishara S, Griffin M, Cargill A, Bali A, Gore ME, Kaye SB, et al. Pretreatment white blood cell subtypes as prognostic indicators in ovarian cancer. Eur J Obstet Gynecol Reprod Biol. Published online 17 July 2007 [epub ahead of print; http://dx.doi.org/10.1016/j.ejogrb.2007.05.012].
  12. De Angulo G, Yuen C, Palla SL, Anderson PM, Zweidler- McKay PA. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. Cancer 2008; 112: 407-15. https://doi.org/10.1002/cncr.23168
  13. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005; 91: 181-4. https://doi.org/10.1002/jso.20329
  14. Cho SH, Cho HB, Nam A, Kim HY, Choi YS, Park KH, et al. Neutrophil-to-lymphocyte ratio as an adjunct to CA 125 for the diagnosis of endometriosis. Fertil Steril 2008; 90: 2073-9. https://doi.org/10.1016/j.fertnstert.2008.03.061
  15. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 1979; 5: 957-71. https://doi.org/10.1007/BF01542654
  16. Matalliotakis I, Panidis D, Vlassis G, Neonaki M, Goumenou A, Koumantakis E. Unexpected increase of the CA 19-9 tumour marker in patients with endometriosis. Eur J Gynaecol Oncol 1998; 19: 498-500.
  17. Harada T, Kubota T, Aso T. Usefulness of CA19-9 versus CA 125 for the diagnosis of endometriosis. Fertil Steril 2002; 78: 733-9. https://doi.org/10.1016/S0015-0282(02)03328-9
  18. Vigano P, Somigliana E, Gaffuri B, Santorsola R, Busacca M, Vignali M. Endometrial release of soluble intercellular adhesion molecule 1 and endometriosis: relationship to the extent of the disease. Obstet Gynecol 2000; 95: 115-8. https://doi.org/10.1016/S0029-7844(99)00465-2
  19. De Placido G, Alviggi C, Di Palma G, Carravetta C, Matarese G, Landino G, et al. Serum concentrations of soluble human leukocyte class I antigens and of the soluble intercellular adhesion molecule-1 in endometriosis: relationship with stage and non-pigmented peritoneal lesions. Hum Reprod 1998; 13: 3206-10. https://doi.org/10.1093/humrep/13.11.3206
  20. Wu MH, Yang BC, Hsu CC, Lee YC, Huang KE. The expression of soluble intercellular adhesion molecule-1 in endometriosis. Fertil Steril 1998; 70: 1139-42. https://doi.org/10.1016/S0015-0282(98)00384-7
  21. Daniel Y, Geva E, Amit A, Eshed-Englender T, Baram A, Fait G, et al. Do soluble cell adhesion molecules play a role in endometriosis? Am J Reprod Immunol 2000; 43: 160-6. https://doi.org/10.1111/j.8755-8920.2000.430305.x
  22. Matalliotakis IM, Vassiliadis S, Goumenou AG, Athanassakis I, Koumantakis GE, Neonaki MA, et al. Soluble ICAM-1 levels in the serum of endometriotic patients appear to be independent of medical treatment. J Reprod Immunol 2001;51: 9-19. https://doi.org/10.1016/S0165-0378(01)00064-X
  23. Somigliana E, Vigano P, Candiani M, Felicetta I, Di Blasio AM, Vignali M. Use of serum-soluble intercellular adhesion molecule-1 as a new marker of endometriosis. Fertil Steril 2002; 77: 1028-31. https://doi.org/10.1016/S0015-0282(02)02971-0
  24. Taylor RN, Levoric DI, Mueller MD. Angiogenic factors in endometriosis. Ann N Y Acad Sci 2002; 955: 90-100.
  25. Aref S, El Sherbiny M, Goda T, Fouda M, Al Askalany H, Abdalla D: Soluble VEGF / sFLt1 ratio is an independent predictor of AML patient outcome. Hematology 2005; 10: 131-4. https://doi.org/10.1080/10245330500065797
  26. Ilhan N, Ilhan N, Deveci F. Functional significance of vascular endothelial growth factor and its receptor (receptor-1) in various lung cancer types. Clin Biochem 2004; 37: 840-5. https://doi.org/10.1016/j.clinbiochem.2004.03.012
  27. Kumar H, Heer K, Greenman J, Kerin MJ, Monson JR. Soluble FLT-1 is detectable in the sera of colorectal and breast cancer patients. Anticancer Res 2002; 22: 1877-80.
  28. Cho SH, Oh YJ, Nam A, Kim HY, Park JH, Kim JH, et al. Evaluation of serum and urinary angiogenic factors in patients with endometriosis. Am J Reprod Immunol 2007; 58: 497-504. https://doi.org/10.1111/j.1600-0897.2007.00535.x
  29. Hsu CC, Yang BC, Wu MH, Huang KE. Enhanced interleukin- 4 expression in patients with endometriosis. Fertil Steril 1997; 67: 1059-64. https://doi.org/10.1016/S0015-0282(97)81439-2
  30. Tsudo T, Harada T, Iwabe T, Tanikawa M, Nagano Y, Ito M, et al. Altered gene expression and secretion of interleukin-6 in stromal cells derived from endometriotic tissues. Fertil Steril 2000; 73: 205-11. https://doi.org/10.1016/S0015-0282(99)00496-3
  31. Syrop CH, Halme J. Peritoneal fluid environment and infertility. Fertil Steril 1987; 48: 1-9.
  32. Syrop CH, Halme J. Cyclic changes of peritoneal fluid parameters in normal and infertile patients. Obstet Gynecol 1987; 69: 416-8.
  33. Halme J, Becker S, Wing R. Accentuated cyclic activation of peritoneal macrophages in patients with endometriosis. Am J Obstet Gynecol 1984; 148: 85-90. https://doi.org/10.1016/S0002-9378(84)80037-X
  34. Bedaiwy MA, Falcone T, Sharma RK, Goldberg JM, Attaran M, Nelson DR, et al. Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial. Hum Reprod 2002; 17: 426-31. https://doi.org/10.1093/humrep/17.2.426
  35. Van Langendonckt A, Casanas-Roux F, Donnez J. Iron overload in the peritoneal cavity of women with pelvic endometriosis. Fertil Steril 2002; 78: 712-8. https://doi.org/10.1016/S0015-0282(02)03346-0
  36. Philippeaux MM, Piguet PF. Expression of tumor necrosis factor-alpha and its mRNA in the endometrial mucosa during the menstrual cycle. Am J Pathol 1993; 143: 480-6.
  37. Hunt JS, Chen HL, Hu XL, Tabibzadeh S. Tumor necrosis factor-alpha messenger ribonucleic acid and protein in human endometrium. Biol Reprod 1992; 47: 141-7. https://doi.org/10.1095/biolreprod47.1.141
  38. Eisermann J, Gast MJ, Pineda J, Odem RR, Collins JL.Tumor necrosis factor in peritoneal fluid of women undergoing laparoscopic surgery. Fertil Steril 1988; 50: 573-9. https://doi.org/10.1016/S0015-0282(16)60185-1
  39. Braun DP, Ding J, Dmowski WP. Peritoneal fluid-mediated enhancement of eutopic and ectopic endometrial cell proliferation is dependent on tumor necrosis factor-alpha in women with endometriosis. Fertil Steril 2002; 78: 727-32. https://doi.org/10.1016/S0015-0282(02)03318-6
  40. Nothnick WB. Treating endometriosis as an autoimmune disease. Fertil Steril 2001; 76: 223-31, 17: 426-31.
  41. Laird SM, Li TC, Bolton AE. The production of placental protein 14 and interleukin 6 by human endometrial cells in culture. Hum Reprod 1993; 8: 793-8. https://doi.org/10.1093/oxfordjournals.humrep.a138144
  42. Rier SE, Parsons AK, Becker JL. Altered interleukin-6 production by peritoneal leukocytes from patients with endometriosis. Fertil Steril 1994; 61: 294-9. https://doi.org/10.1016/S0015-0282(16)56520-0
  43. Tseng JF, Ryan IP, Milam TD, Murai JT, Schriock ED, Landers DV, et al. Interleukin-6 secretion in vitro is upregulated in ectopic and eutopic endometrial stromal cells from women with endometriosis. J Clin Endocrinol Metab 1996; 81: 1118-22. https://doi.org/10.1210/jc.81.3.1118
  44. Koyama N, Matsuura K, Okamura H. Cytokines in the peritoneal fluid of patients with endometriosis. Int J Gynaecol Obstet 1993; 43: 45-50. https://doi.org/10.1016/0020-7292(93)90273-Y
  45. Harada T, Yoshioka H, Yoshida S, Iwabe T, Onohara Y, Tanikawa M, et al. Increased interleukin-6 levels in peritoneal fluid of infertile patients with active endometriosis. Am J Obstet Gynecol 1997; 176: 593-7. https://doi.org/10.1016/S0002-9378(97)70553-2
  46. Taylor RN, Ryan IP, Moore ES, Hornung D, Shifren JL, Tseng JF. Angiogenesis and macrophage activation in endometriosis. Ann N Y Acad Sci 1997; 828: 194-207. https://doi.org/10.1111/j.1749-6632.1997.tb48540.x
  47. Lebovic DI, Mueller MD, Taylor RN. Vascular endothelial growth factor in reproductive biology. Curr Opin Obstet Gynecol 1999; 11: 255-60. https://doi.org/10.1097/00001703-199906000-00004
  48. D'Angelo G, Struman I, Martial J, Weiner RI. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci USA 1995; 92: 6374-8. https://doi.org/10.1073/pnas.92.14.6374
  49. Dvorak HN, Senger DR, Dvorak AM, Harvey VS, McDonagh J. Regulation of extravascular coagulation bmicrovascular permeability. Science 1985; 227: 1059-61. https://doi.org/10.1126/science.3975602
  50. Shifren JL, Tseng JF, Zaloudek CJ, Ryan IP, Meng YG, Ferrara N, et al. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J Clin Endocrinol Metab 1996; 81: 3112-8. https://doi.org/10.1210/jc.81.8.3112
  51. Donnez J, Smoes P, Gillerot S, Casanas-Roux F, Nisolle M. Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod 1998; 13: 1686-90. https://doi.org/10.1093/humrep/13.6.1686
  52. Ortiz BD, Krensky AM, Nelson PJ. Kinetics of transcription factors regulating the RANTES chemokine gene reveal a developmental switch in nuclear events during T-lymphocyte maturation. Mol Cell Biol 1996; 16: 202-10. https://doi.org/10.1128/MCB.16.1.202
  53. Hornung D, Ryan IP, Chao VA, Vigne JL, Schriock ED, Taylor RN. Immunolocalization and regulation of the chemokine RANTES in human endometrial and endometriosis tissues and cells. J Clin Endocrinol Metab 1997; 82: 1621-8. https://doi.org/10.1210/jc.82.5.1621
  54. Simon C, Frances A, Piquette GN, el Danasouri I, Zurawski G, Dang W, et al. Embryonic implantation in mice is blocked by interleukin-1 receptor antagonist. Endocrinology 1994; 134: 521-8. https://doi.org/10.1210/en.134.2.521
  55. Taketani Y, Kuo TM, Mizuno M. Comparison of cytokine levels and embryo toxicity in peritoneal fluid in infertile women with untreated or treated endometriosis. Am J Obstet Gynecol 1992; 167: 265-70. https://doi.org/10.1016/S0002-9378(11)91672-X
  56. Stefansson H, Geirsson RT, Steinthorsdottir V, Jonsson H, Manolescu A, Kong A, et al. Genetic factors contribute to the risk of developing endometriosis. Hum Reprod 2002; 17: 555 -9. https://doi.org/10.1093/humrep/17.3.555
  57. Taylor RN, Lundeen SG, Giudice LC. Emerging role of genomics in endometriosis research. Fertil Steril 2002; 78: 694-8. https://doi.org/10.1016/S0015-0282(02)03325-3
  58. Vaisse C, Atger M, Potier B, Milgrom E. Human placental protein 14 gene: sequence and characterization of a short duplication. DNA Cell Biol 1990; 9: 401-13. https://doi.org/10.1089/dna.1990.9.401
  59. Kao LC, Tulac S, Lobo S, Imani B, Yang JP, Germeyer A, et al. Global gene profiling in human endometrium during the window of implantation. Endocrinology 2002; 143: 2119-38. https://doi.org/10.1210/en.143.6.2119
  60. Yan SF, Fujita T, Lu J, Okada K, Shan Zou Y, Mackman N, et al. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med 2000; 6: 1355-61. https://doi.org/10.1038/82168
  61. Yan SF, Pinsky DJ, Mackman N, Stern DM. Egr-1: is it always immediate and early? J Clin Invest 2000; 105: 553-4. https://doi.org/10.1172/JCI9513
  62. Vidal F, Aragones J, Alfranca A, de Landazuri MO. Upregulation of vascular endothelial growth factor receptor Flt-1 after endothelial denudation: role of transcription factor Egr-1. Blood 2000; 95: 3387-95.
  63. Eyster KM, Boles AL, Brannian JD, Hansen KA. DNA microarray analysis of gene expression markers of endometriosis. Fertil Steril 2002; 77: 38-42. https://doi.org/10.1016/S0015-0282(01)02955-7
  64. Kitawaki J, Noguchi T, Amatsu T, Maeda K, Tsukamoto K, Yamamoto T, et al. Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium. Biol Reprod 1997; 57: 514-9. https://doi.org/10.1095/biolreprod57.3.514
  65. Dheenadayalu K, Mak I, Gordts S, Campo R, Higham J, Puttemans P, et al. Aromatase P450 messenger RNA expressionin eutopic endometrium is not a specific marker for pelvic endometriosis. Fertil Steril 2002; 78: 825-9. https://doi.org/10.1016/S0015-0282(02)03324-1
  66. Takayama K, Zeitoun K, Gunby RT, Sasano H, Carr BR, Bulun SE. Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril 1998; 69: 709-13. https://doi.org/10.1016/S0015-0282(98)00022-3
  67. Bulun SE, Zeitoun K, Takayama K, Noble L, Michael D, Simpson E, et al. Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis. Endocr Relat Cancer 1999; 6: 293-301. https://doi.org/10.1677/erc.0.0060293
  68. Zeitoun KM, Bulun SE. Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil Steril 1999; 72: 961-9. https://doi.org/10.1016/S0015-0282(99)00393-3
  69. Bulun SE, Zeitoun KM, Takayama K, Simpson E, Sasano H. Aromatase as a therapeutic target in endometriosis. Trends Endocrinol Metab 2000; 11: 22-7. https://doi.org/10.1016/S1043-2760(99)00216-7
  70. Bouquet de Joliniere J, Validire P, Canis M, Doussau M, Levardon M, Gogusev J. Human endometriosis-derived permanent cell line (FbEM-1): establishment and characterization. Hum Reprod Update 1997; 3: 117-23. https://doi.org/10.1093/humupd/3.2.117
  71. Mai KT, Yazdi HM, Perkins DG, Parks W. Pathogenetic role of the stromal cells in endometriosis and adenomyosis. Histopathology 1997; 30: 430-42. https://doi.org/10.1046/j.1365-2559.1997.4910725.x
  72. Matthews CJ, Redfern CP, Hirst BH, Thomas EJ. Character ization of human purified epithelial and stromal cells from endometrium and endometriosis in tissue culture. Fertil Steril 1992; 57: 990-7. https://doi.org/10.1016/S0015-0282(16)55014-6
  73. Nisolle M, Casanas-Roux F, Donnez J. Immunohistochemical analysis of proliferative activity and steroid receptor expression in peritoneal and ovarian endometriosis. Fertil Steril 1997; 68: 912-9. https://doi.org/10.1016/S0015-0282(97)00341-5
  74. Jiang J, Wu R, Wang Z, Sun H, Xu Z, Xiu H. Effect of mifepristone on estrogen and progesterone receptors in human endometrial and endometriotic cells in vitro. Fertil Steril 2002; 77: 995-1000. https://doi.org/10.1016/S0015-0282(02)03081-9
  75. Evers JL, Dunselman GA, Van der Linden PJ. Markers for endometriosis. Baillieres Clin Obstet Gynaecol 1993; 7: 715 -39. https://doi.org/10.1016/S0950-3552(05)80460-2
  76. Reinholt FP, Hultenby K, Oldberg A, Heinegard D. Osteopontin - a possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA 1990; 87: 4473-5. https://doi.org/10.1073/pnas.87.12.4473
  77. Brown LF, Berse B, Van de Water L, Papadopoulos-Sergiou A, Perruzzi CA, Manseau EJ, Dvorak HF, Senger DR. Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell 1992; 3: 1169-80. https://doi.org/10.1091/mbc.3.10.1169
  78. Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mansson H. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 1087-97. https://doi.org/10.1158/1055-9965.EPI-06-1008
  79. Hu DD, Lin EC, Kovach NL, Hoyer JR, Smith JW. A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J Biol Chem 1995; 270: 26232-38. https://doi.org/10.1074/jbc.270.44.26232
  80. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, Giachelli CM. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 1995; 95: 713 -24. https://doi.org/10.1172/JCI117718
  81. Apparao KB, Murray MJ, Fritz MA, Meyer WR, Chambers AF, Truong PR, Lessey BA. Osteopontin and its receptor alpha v beta(3) integrin are coexpressed in the human endometrium during the menstrual cycle but regulated differentially. J Clin Endocrinol Metab 2001; 86: 4991-5000. https://doi.org/10.1210/jc.86.10.4991
  82. Odagiri K, Konno R, Fujiwara H, Netsu S, Ohwada M, Shibahara H, Suzuki M. Immunohistochemical study of osteopontin and L-selectin in a rat endometriosis model and in human endometriosis. Fertil Steril 2007; 88: 1207-11. https://doi.org/10.1016/j.fertnstert.2007.02.007
  83. Cho SH, Ahn YS, Choi YS, Seo SK, Nam A, Kim HY, et al. Endometrial osteoponin mRNA expression and Plasma osteopontin levels are increased in patients with endometriosis. Am J Reprod Immunol 2009; 61: 286-93. https://doi.org/10.1111/j.1600-0897.2009.00692.x
  84. Marcoux S, Maheux R, Berube S. Laparoscopic surgery in infertile women with minimal or mild endometriosis. Canadian Collaborative Group on Endometriosis. N Engl J Med 1997; 337: 217-22. https://doi.org/10.1056/NEJM199707243370401